STRUCTURAL ELEMENTS OF NICOTINIC ACETYLCHOLINE RECEPTORS
STRUCTURAL ELEMENTS OF NICOTINIC ACETYLCHOLINE RECEPTORS
批准号:
2460574
负责人:
ROGER L PAPKE
金额:
$19.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-08-01 至 1999-07-31
关键词:
Xenopus Xenopus oocyte antisense nucleic acid calcium flux chemical binding chimeric proteins mecamylamine molecular cloning molecular site neuropharmacology nicotinic receptors oligonucleotides piperidine polymerase chain reaction protein structure function site directed mutagenesis voltage /patch clamp
中文摘要
最近,我们对生物学的认识有了新的进展。
烟碱型乙酰胆碱受体可能在
大脑,克隆这些受体的基因给了我们
研究这些受体的详细分子机制的工具[l]。
已知尼古丁受体参与成瘾过程[2],
并被认为是精神分裂症的影响[3,4]。他们有
也被证明对认知过程和记忆很重要。
烟碱激动剂正被开发作为治疗
老年痴呆症[5]。沿着人们对
烟碱受体在脑功能中可能发挥的功能作用,
来欣赏存在于细胞中的多种受体亚型,
个脑袋这一建议将扩大我们的理解,如何一个关键的
生理特性,二价离子的渗透性,受到调节
在受体亚型(即亚基组合)的水平上,
在特定的蛋白质结构域方面。二价离子渗透性可以是
与学习和记忆相关的神经元可塑性所需的
并且还可能产生兴奋性毒性。
我们将在非洲爪蟾卵母细胞中表达克隆的烟碱受体,
嵌合和突变亚基的研究,我们将确定分子
调节钙渗透性的元素,以及分子
与受体的使用依赖性抑制有关的元素。
通过评估调节这些因素之间的关系,
二价离子渗透性,以及与敏感性相关的那些
对于特定的拮抗剂,可以定义
可以靶向特定的功能重要的受体亚型,
避开那些对认知过程很重要的受体,
那些参与成瘾过程,或选择性地阻止那些
可能会使细胞处于毒性的危险中。
将进行受体生理学和药理学的分析
无论是在全细胞电流的水平上,
单通道属性。对相关系列的研究
双功能抑制剂将允许抑制性结合的处置
待评价的受体复合物内的位点。
我们广泛的初步数据为我们提供了强有力的基础,
实验设计的方法和候选序列,
重要的结构域。我们有证据表明二价离子
渗透性由肌肉受体的γ亚单位调节,
神经元受体的α 5亚单位。该模型将直接
用反义基因敲除实验进行评价,
这些亚基在天然受体中的功能影响。
该提案中的实验将提供重要的新见解,
大脑的烟碱受体在生物物理学上
性质,它们作为治疗靶点的潜力,以及它们之间的关系
特定的功能特性和药物敏感性之间的关系。
英文摘要
Recently new advances have been made in our understanding of the
functional roles which nicotinic acetylcholine receptors may play in the
brain, and the cloning of the genes for these receptors has given us the
tools to study the detailed molecular mechanism of these receptors [l].
Nicotinic receptors are known to be involved in addictive processes[2],
and have been suggested to be affected in schizophrenia [3, 4]. They have
also been shown to be important for cognitive processes and memory.
Nicotinic agonists are being developed as therapeutics for the treatment
of Alzheimer's dementia [5]. Along with an increased understanding of the
functional roles that nicotinic receptors may play in brain function has
come an appreciation for the multiple receptor subtypes that exist in the
brain. This proposal will extend our understanding of how a crucial
physiological property, the permeability to divalent ions, is regulated
both on the level of receptor subtype (i.e. subunit combination) and also
in terms of the specific protein domains. Divalent ion permeability may be
required for the neuronal plasticity associated with learning and memory
and may also create a potential for excitotoxicity.
We will express cloned nicotinic receptors in Xenopus oocytes, and with
the study of chimeric and mutant subunits, we will identify the molecular
elements that regulate calcium permeability, as well as the molecular
elements that are involved with use-dependent inhibition of the receptors.
By evaluating the relationships between the elements that regulate
divalent ion permeability, and those which are associated with sensitivity
to specific antagonists it may be possible to define therapeutics which
may target specific functionally important receptor subtypes, either to
spare those receptors important for cognitive processes, while targeting
those involved in addictive processes, or to selectively block those which
may put cells at risk of toxicity.
The analysis of receptor physiology and pharmacology will be carried out
both at the level of whole-cell currents and in terms of a detailed study
of single channel properties. The study of a related series of
bifunctional inhibitors will permit the disposition of inhibitory binding
sites within the receptor complex to be evaluated.
Our extensive preliminary data has provided us with a strong basis for
experimental design in terms of approaches and candidate sequences for
important structural domains. We have evidence that divalent ion
permeability is regulated by the gamma subunits of muscle receptors and
the alpha5 subunits of neuronal receptors. This model will be directly
evaluated with antisense knockout experiments directed at eliminating the
functional influences of these subunits in native receptors.
The experiments in this proposal will provide important new insights into
the nicotinic receptors of the brain in terms of their biophysical
properties, their potential as therapeutic targets, and relationships
between specific functional properties and drug sensitivity.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain.
美加明和尼古丁的拮抗活性显示出对第二跨膜结构域中的β亚基序列的相互依赖性。
DOI:
10.1038/sj.bjp.0702686
发表时间:
1999
期刊:
British journal of pharmacology
影响因子:
7.3
作者:
[Webster,JC, Francis,MM, Porter,JK, Robinson,G, Stokes,C, Horenstein,B, Papke,RL]
通讯作者:
Papke,RL
alpha7 receptor-selective agonists and modes of alpha7 receptor activation.
α7 受体选择性激动剂和 α7 受体激活模式。
DOI:
10.1016/s0014-2999(00)00009-1
发表时间:
2000
期刊:
European journal of pharmacology
影响因子:
5
作者:
[Papke,RL, Meyer,E, Nutter,T, Uteshev,VV]
通讯作者:
Uteshev,VV
Enhanced inhibition of a mutant neuronal nicotinic acetylcholine receptor by agonists: protection of function by (E)-N-methyl-4-(3-pyridinyl)-3-butene-1-amine (TC-2403).
激动剂增强突变神经元烟碱乙酰胆碱受体的抑制:(E)-N-甲基-4-(3-吡啶基)-3-丁烯-1-胺 (TC-2403) 保护功能。
DOI:
10.1124/jpet.301.2.765
发表时间:
2002
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
[Papke,RogerL]
通讯作者:
Papke,RogerL
DOI:
--
发表时间:
1998-12
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
[E. Meyer;A. Kuryatov;V. Gerzanich;J. Lindstrom;R. Papke]
通讯作者:
E. Meyer;A. Kuryatov;V. Gerzanich;J. Lindstrom;R. Papke
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS
-
批准号:6636246
-
项目类别:
-
资助金额:$25.16万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting alpha7 nAChR for Therapeutic Effects
-
批准号:7107980
-
项目类别:
-
资助金额:$31.97万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of alpha7 nAChR for therapeutic effects
-
批准号:8608533
-
项目类别:
-
资助金额:$42.22万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS
-
批准号:6044455
-
项目类别:
-
资助金额:$23.05万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of alpha7 nAChR for therapeutic effects
-
批准号:9205232
-
项目类别:
-
资助金额:$42.46万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of Alpha7 nAChR for therapeutic effects
-
批准号:10551732
-
项目类别:
-
资助金额:$45.65万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of Alpha7 nAChR for therapeutic effects
-
批准号:10331721
-
项目类别:
-
资助金额:$45.68万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting alpha7 nAChR for Therapeutic Effects
-
批准号:6984700
-
项目类别:
-
资助金额:$32.47万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of Alpha7 nAChR for therapeutic effects
-
批准号:10091463
-
项目类别:
-
资助金额:$46.39万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting alpha7 nAChR for Therapeutic Effects
-
批准号:7259343
-
项目类别:
-
资助金额:$31.04万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS
-
批准号:6386881
-
项目类别:
-
资助金额:$23.73万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
TARGETING ALPHA7 NACHR FOR THERAPEUTICS EFFECTS
-
批准号:6519875
-
项目类别:
-
资助金额:$24.44万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of alpha7 nAChR for therapeutic effects
-
批准号:8041431
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of alpha7 nAChR for therapeutic effects
-
批准号:8214527
-
项目类别:
-
资助金额:$43.33万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of Alpha7 nAChR for therapeutic effects
-
批准号:9883965
-
项目类别:
-
资助金额:$50.85万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting alpha7 nAChR for Therapeutic Effects
-
批准号:7469961
-
项目类别:
-
资助金额:$30.14万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting of alpha7 nAChR for therapeutic effects
-
批准号:8423035
-
项目类别:
-
资助金额:$40.74万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
Targeting alpha7 nAChR for Therapeutic Effects
-
批准号:8050354
-
项目类别:
-
资助金额:$7.32万
-
财政年份:2000
-
负责人:ROGER L PAPKE
-
依托单位:
STRUCTURAL ELEMENTS OF NICOTINIC ACETYLCHOLINE RECEPTORS
-
批准号:2271385
-
项目类别:
-
资助金额:$17.19万
-
财政年份:1995
-
负责人:ROGER L PAPKE
-
依托单位:
STRUCTURAL ELEMENTS OF NICOTINIC ACETYLCHOLINE RECEPTORS
-
批准号:2271386
-
项目类别:
-
资助金额:$18.32万
-
财政年份:1995
-
负责人:ROGER L PAPKE
-
依托单位:
海外基金